@chris_practical's TRT optimization claims, fact-checked

What did @chris_practical actually say?

The core argument here is that testosterone alone is rarely enough, and that clinics are leaving patients under-optimized by only offering HCG, an aromatase inhibitor, and testosterone. Chris suggests that compounds like DHEA, primobolan, and masteron are legitimate long-term additions to a TRT protocol. He also warns that the honeymoon phase ending should not drop you back to "natural" baseline levels, and offers to personally refine protocols for followers via DM.

There are a few things worth separating out here: the general point about protocol individualization has real clinical backing. The specific compound recommendations are where things get complicated fast.

Does the science back this up?

Partially, but the add-on stack he describes goes well beyond what the evidence supports for standard hypogonadism management. The honeymoon phase observation is real and documented. The case for DHEA is modest. The case for primobolan and masteron as TRT "add-ons" is essentially bodybuilding culture dressed up as clinical practice.

On the honeymoon phase: testosterone therapy does produce early-phase improvements in mood, energy, and libido that can attenuate over time. A 2017 study by Snyder et al. in the New England Journal of Medicine confirmed sexual function improvements with testosterone therapy, though long-term maintenance of those benefits varies significantly by individual. If a patient's symptoms fully regress to pre-treatment levels, that warrants a clinical investigation, not just a protocol tweak.

On DHEA: evidence is genuinely mixed. A 2006 Cochrane review found limited benefit for DHEA supplementation in adrenal insufficiency, with minimal data supporting its use in otherwise hypogonadal men on TRT. It is not a standard-of-care addition.

On primobolan and masteron: these are anabolic-androgenic steroids, not FDA-approved treatments for hypogonadism. Using them as TRT "add-ons" crosses from hormone optimization into performance-enhancing drug use. There is no peer-reviewed clinical trial evidence supporting their routine use in TRT protocols.

What did they get wrong (or right)?

Credit where it is due: the observation that many clinics run cookie-cutter protocols is a legitimate criticism. Research on TRT optimization, including a 2019 analysis by Khera et al. in the Journal of Sexual Medicine, has shown that individualized dosing and monitoring improves patient outcomes compared to standardized protocols. The broader point about protocol refinement is reasonable.

What he got wrong, or at least significantly oversimplified, is the leap from "clinics are under-optimizing" to "add primobolan or masteron." Those are injectable anabolic steroids used primarily in bodybuilding contexts. Recommending them as casual long-term additions normalizes what is effectively an off-label AAS stack. He frames this as a quality-of-life upgrade. Clinically, it introduces cardiovascular risk, lipid dysregulation, and endocrine suppression without established therapeutic benefit for hypogonadism specifically.

The offer to "DM me help" and personally refine protocols for followers is also worth flagging. That is not how regulated telehealth works, and it is not a safe substitute for a licensed provider with access to labs and patient history.

What should you actually know?

If your TRT honeymoon phase has ended and you feel like you are back to baseline, that is a real clinical problem worth investigating. But the investigation should start with blood work, not an expanded compound list. Low or inconsistent testosterone levels, sub-optimal SHBG, high estradiol, thyroid dysfunction, or sleep disorders can all mimic the feeling of under-optimized TRT. Snyder et al. (2016, NEJM) noted that symptom response to testosterone is multi-factorial, not a simple dose-response curve.

DHEA is an over-the-counter supplement in the US and has a low harm profile at typical doses, but evidence for meaningful benefit in TRT patients specifically is thin. It is not a standard add-on in endocrinology guidelines from the American Urological Association or the Endocrine Society.

Primobolan and masteron are controlled substances. In the US, they fall under Schedule III of the Controlled Substances Act. Their use outside of a medically supervised and legally compliant framework is not hormone optimization. It is anabolic steroid use. That distinction matters, both legally and physiologically.

If your current clinic is running a one-size-fits-all protocol and not tracking estradiol, hematocrit, lipids, and PSA regularly, that is a legitimate problem worth addressing. The answer is better monitoring and individualized dosing of approved therapies, not stacking additional anabolic compounds based on social media advice.